FLOWer
Commercial- Indications
- Embolic protection during TAVR
Company intelligence / Profile preview
AorticLab has developed FLOWer™, an innovative embolic protection device for use during TAVI procedures, which is CE marked and now entering commercialization in Europe. The company’s Nautilus clinical study demonstrated excellent results for FLOWer™. Additional devices are under development to restore native aortic valve function by debriding calcified leaflets[1][3][6].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AorticLab.